myrbetriq
Generic: mirabegron
Labeler: astellas pharma us, inc.Drug Facts
Product Profile
Brand Name
myrbetriq
Generic Name
mirabegron
Labeler
astellas pharma us, inc.
Dosage Form
GRANULE, FOR SUSPENSION, EXTENDED RELEASE
Routes
Active Ingredients
mirabegron 8 mg/mL
Manufacturer
Identifiers & Regulatory
Product NDC
0469-5020
Product ID
0469-5020_fe8998d8-cf08-4e07-b966-33e8de20abf1
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
NDA
Application Number
NDA213801
Listing Expiration
2026-12-31
Marketing Start
2021-03-25
Pharmacologic Class
Established (EPC)
Mechanism of Action
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
04695020
Hyphenated Format
0469-5020
Supplemental Identifiers
RxCUI
UNII
NUI
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
myrbetriq (source: ndc)
Generic Name
mirabegron (source: ndc)
Application Number
NDA213801 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 8 mg/mL
Packaging
- 1 BOTTLE in 1 CARTON (0469-5020-99) / 100 mL in 1 BOTTLE
Packages (1)
Ingredients (1)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "fe8998d8-cf08-4e07-b966-33e8de20abf1", "openfda": {"nui": ["N0000185008", "N0000185007", "N0000182137", "N0000190114", "N0000185503"], "unii": ["MVR3JL3B2V"], "rxcui": ["1300791", "1300797", "1300801", "1300803", "2541233", "2541237"], "spl_set_id": ["ba9e9e15-e666-4c56-9271-2e24739cfa2d"], "pharm_class_epc": ["beta3-Adrenergic Agonist [EPC]"], "pharm_class_moa": ["Adrenergic beta3-Agonists [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "manufacturer_name": ["Astellas Pharma US, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 BOTTLE in 1 CARTON (0469-5020-99) / 100 mL in 1 BOTTLE", "package_ndc": "0469-5020-99", "marketing_start_date": "20210325"}], "brand_name": "Myrbetriq", "product_id": "0469-5020_fe8998d8-cf08-4e07-b966-33e8de20abf1", "dosage_form": "GRANULE, FOR SUSPENSION, EXTENDED RELEASE", "pharm_class": ["Adrenergic beta3-Agonists [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "beta3-Adrenergic Agonist [EPC]"], "product_ndc": "0469-5020", "generic_name": "mirabegron", "labeler_name": "Astellas Pharma US, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Myrbetriq", "active_ingredients": [{"name": "MIRABEGRON", "strength": "8 mg/mL"}], "application_number": "NDA213801", "marketing_category": "NDA", "marketing_start_date": "20210325", "listing_expiration_date": "20261231"}